However, PPARα was downregulated in patients with NASH compared to both patients with steatosis and healthy controls [124,125], and the expression of PPARα decreases with increasing NAFLD activity score and progression of fibrosis [124]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.